Markey Shared Resource Facilities

Fulfilling the Scientific Needs of MCC Investigators


Provides statistical expertise to ensure rigor and enhance the execution of scientific research.

Biospecimen Procurement and Translational Pathology (BPTP)

Collects, processes, annotates, stores and distributes biospecimens to support translational research.
Learn More


Develops and sustains biomedical informatics expertise and resources to enable and accelerate research.
Learn More

Flow Cytometry and Immune Monitoring

Provides access to flow cytometric cell analysis and/or sorting or other immune-based cell assays.


Provides cutting-edge genomic and molecular technology services.

Patient-oriented and Population Sciences

Provides psychosocial, behavioral, and epidemiologic assistance.


Provides expertise in redox metabolism, oxidative stress, mitochondrial function, proteomics, and metabolomics.

Overview of MCC Shared Resource Facilities

The services offered by these facilities foster and facilitate advances in the prevention, early detection and management of cancer. These combined resources support a broad spectrum of molecular, cellular, animal, human and behavioral/epidemiology studies for advancement of the overall mission of the center. Each SRF has the capacity to contribute to the entire translational continuum, from basic and preclinical studies to translational, bioinformatics, clinical, cancer control/prevention, epidemiologic and population-based studies. 

Specific Aims

  1. Promote state-of-the-art technology, methodologic and content expertise to foster the MCC scientific strategies in its three Research Programs.
  2. Conduct rigorous monitoring and evaluation processes and support financial health for stability of the SRF infrastructure.
  3. Facilitate robust and stable access to MCC shared resources through innovative initiatives.

All Markey Shared Resource Facilities follow the following criteria for prioritization of services:

  1. MCC members with cancer-related, peer-reviewed studies.
  2. MCC investigators funded on cancer-related, non-peer-reviewed grants and preparing peer-reviewed grant applications.
  3. MCC investigators applying for pilot funding and MCC IIT development.
  4. MCC investigators not currently funded.

Pricing: Refer to each SRF for pricing or contact the Director or Operations Manager with specific questions.
Subsidy: MCC provides SRF specific subsidies to MCC members to ensure accessibility. 

Shared Resource Facility Management Office (SRFMO) 

A dedicated office that provides centralized coordination and communication across all SRFs and with other MCC research entities. The SRFMO: 1) takes the lead in strategizing and implementing management aspects across all SRFs; 2) implements defined processes for determining scientific needs, monitoring, and evaluation including annual satisfaction and ad-hoc member surveys; 3) employs strategies for ensuring accessibility of MCC-managed as well as jointly managed institutional facilities; and 4) works closely with MCC Administration on the full scope of financial, human resource, marketing and reporting activities of SRFs.

heidi weiss
Heidi Weiss, PhD

SRF Associate Director
therese bocklage
Thèrése Bocklage, MD

SRF Assistant Director
chang liu
Chang Liu, MPA

SRF Administrator
Dr. Weiss leads the coordination of the technical and scientific functions of the SRFs and determines strategies and processes for optimal access and efficient provision of SRF services. Dr. Bocklage further assesses the technical and operational aspects of laboratory-based facilities and enhances the engagement of those facilities in the coordinated delivery of services across the SRFs. Ms. Liu handles day-to-day operations and communications in the management of all SRFs.

SRF Oversight Organizational Structure

sr management org chart


Interactivity of SRFs to Support a ResearcherOmics workflow

  1. Process for an Omics Concierge system. The SRFMO works closely with SRF Directors to facilitate implementation of workflows for coordinated access and hand-offs between MCC SRFs.
  2. Process for support of investigator initiated clinical trials. Access to SRFs is integrated with MCC’s clinical research entities, and multiple SRFs support specific IITs depending on trial design, clinical, correlative and quality of life endpoint goals.

FCIM New Instrumentation

isoplexis machine

The newest instrumentation in the FCIM SRF is IsoSpark Single-Cell Proteomics System by IsoPlexis.  You can now perform functional proteomic analysis for secreted or intracellular proteins on individual cells.  The phenotype of individual cells can be determined for their secretome or phosphoproteomic signaling networks by multiplex analysis of up to 30 separate proteins.  Cell suspensions are loaded into a barcoded IsoCode Chip, which captures individual cells in microchambers.  Barcoded antibodies surrounding individual cells trap proteins secreted or released from lysed cells to generate a functional proteomic phenotype for each cell.


Proprietary software offers a variety of visualizations of results including 3D t-SNE mapping, single cell polyfunctional heat maps, protein intensities by single cells, and others.  

Contact FCIM staff to schedule a meeting to discuss how Single-Cell Proteomics can help in your research efforts.

Should you have any questions about SRF services, please contact Chang Liu at

quotation marks

Acknowledge the SRFs in Your Publications! 

If your research used an SRF service and/or an SRF member provided intellectual input or collaborative support, use the following statement to acknowledge Markey Cancer Center shared resources:

“This research was supported by the _______ Shared Resource(s) of the University of Kentucky Markey Cancer Center (P30CA177558).”

This acknowledgment is necessary for publications and should be used for research papers, publications, and grant applications.

Markey Cancer Center is NCI-designated

The UK Markey Cancer Center was first designated by the National Cancer Institute in 2013 – a distinction that recognizes our extraordinary ability to provide world-class care for our patients. We are the only NCI-Designated Cancer Center in Kentucky and one of only 71 in the nation.